Tirzepatide Dosage

In clinical trials, tirzepatide was given as a once-weekly subcutaneous injection whose dose was raised gradually over the opening weeks of treatment. In the SURMOUNT-1 obesity trial published in the New England Journal of Medicine (Jastreboff et al., 2022), participants started at a low 2.5 mg weekly dose and stepped up roughly every four weeks toward one of three weekly maintenance tiers — 5 mg, 10 mg or 15 mg — which they then held for the remainder of a 72-week study. That gradual climb, not the weekly cadence, is the defining feature of how tirzepatide was dosed.

There is no validated consumer or at-home tirzepatide protocol. The figures below are trial-design and product-label parameters, reported here as research convention — not a personal dose, not a titration plan for you, and not a recommendation to use any amount. This page answers the informational question of how much tirzepatide was used, how the dose was escalated and how titration ran in studies; it is deliberately separate from the shop, which exists only to supply the research compound. If you want stocked formats and strengths, start at the tirzepatide category hub. If you want to understand the dosing evidence and why the dose is stepped up, read on.

How tirzepatide was dosed in trials

Tirzepatide is a single molecule that activates two receptors at once — GIP and GLP-1 — which is why it is described as a dual agonist. Across the published obesity and diabetes work it was administered once weekly by subcutaneous injection, the same weekly cadence used for semaglutide. The consistent design choice was gradual escalation: no arm began at a high weekly dose. Treatment opened at 2.5 mg weekly and rose in fixed steps until the assigned maintenance dose was reached.

SURMOUNT-1 randomised adults with obesity to placebo or to tirzepatide at weekly maintenance targets of 5 mg, 10 mg or 15 mg. Every active arm began at 2.5 mg per week for the first four weeks — a treatment-initiation dose, not a maintenance dose — and was then raised by 2.5 mg roughly every four weeks across an escalation window of about twenty weeks, after which the dose was held steady through the 72-week treatment period. The SURPASS type-2-diabetes trials used the same escalation logic to reach the same 5 mg, 10 mg and 15 mg tiers.

The trial dose-escalation schedule

The table shows the full escalation to the top 15 mg maintenance tier, following the once-weekly, 2.5 mg-start, four-week-step pattern used across the tirzepatide trials and reflected on the approved product labelling. Arms assigned to a lower maintenance tier simply stopped climbing once they reached 5 mg or 10 mg. The exact week boundaries vary between studies, so treat the schedule as approximate. These are trial and label figures, not a recommended personal dose.

Trial period	Weekly subcutaneous dose (15 mg arm)	Purpose
Weeks 1–4	2.5 mg (starting dose)	Introduce the compound at the lowest step
Weeks 5–8	5 mg	First escalation
Weeks 9–12	7.5 mg	Second escalation
Weeks 13–16	10 mg	Third escalation
Weeks 17–20	12.5 mg	Fourth escalation
Week 21 onward	15 mg (maintenance)	Held to the end of the treatment period

At the top of the range, the 15 mg maintenance dose produced the largest mean body-weight reduction in SURMOUNT-1 — on the order of 21% at 72 weeks, against roughly 15% at 5 mg — while placebo changed little. Those figures describe the trial population as a whole, not a result you should expect or a dose to target.

Why the dose is escalated: GI tolerability

The reason for stepping up slowly is gastrointestinal tolerability. Like other gut-hormone agonists, tirzepatide's most commonly reported adverse events in the trials were gastrointestinal — nausea, diarrhoea, vomiting and constipation — and these were most frequent while the dose was rising. Escalation exists to give that tolerance time to build. Most reported events were mild to moderate and tended to ease as the body adjusted. This is why both the trials and the approved labelling hold each step, starting with the 2.5 mg initiation dose, for at least four weeks before moving up.

Reconstitution and draw volume

Tirzepatide supplied as a lyophilised (freeze-dried) vial is a powder, not a ready-to-use liquid, so it must be reconstituted with bacteriostatic water before any volume can be drawn. The arithmetic is where mistakes happen: the amount of water you add sets the concentration, and the concentration decides how many units on the syringe correspond to a given milligram figure. Add more water and each unit carries less peptide; add less and it carries more.

Do the maths before you touch the vial. Our peptide reconstitution calculator is the core companion to this guide: enter the vial strength, the water volume and your target amount, and it returns the draw volume on a standard insulin syringe. Use it with the HD Labs Tirzepatide 30 vial so the concentration you prepare matches the schedule you are studying. We give the concept here, not a personal dose — what you draw is a decision for a qualified professional, not for this page.

Storage

Tirzepatide is temperature-sensitive. As a general handling matter, the lyophilised powder is kept refrigerated at about 2–8 °C and protected from light and freezing; once reconstituted, the solution is also refrigerated and used within a limited window rather than stored indefinitely. BeSkinny ships temperature-sensitive peptides cold-chain with gel packs to preserve integrity in transit across South Africa. Always defer to the certificate of analysis and any handling notes supplied with your specific batch, which take precedence over general guidance.

What affects tolerability

Several factors shape how the reported tolerability pattern plays out:

• The initiation dose. The 2.5 mg starting dose introduces the compound gently; it is not a maintenance target and was not studied as one.
• Speed of escalation. Longer intervals between steps give tolerance more time to develop; the trials moved up no sooner than every four weeks.
• Maintenance tier. Higher weekly targets carry more of the same class effects, so the 15 mg arm sat at the top of both the efficacy and side-effect range.
• Individual variation. Trial averages hide wide person-to-person differences; group data cannot predict any individual response.

The escalation schedule is best read as a tolerability tool from the study design, not a number to copy. For how the dual agonist compares with semaglutide, see tirzepatide vs semaglutide; for how it compares with the triple agonist, see retatrutide vs tirzepatide; and for the broader safety picture across peptides, see are peptides safe?

Research-use and medical disclaimer

Everything on this page is provided strictly for laboratory and research reference. It is not medical advice, not prescribing advice, and not a human dosing protocol. The doses, escalation steps and outcome figures describe what published clinical trials and approved product labelling reported, cited following standard research-reference convention; they are not instructions, and they are not a validated consumer protocol. BeSkinny supplies tirzepatide as a research compound only and references the molecule factually, not as any branded medicine. Before making any decision about a gut-hormone agonist, consult a registered healthcare professional who can account for your individual circumstances. Nothing here replaces that conversation.

Frequently asked questions

How much tirzepatide was used per week in trials?

In the SURMOUNT-1 obesity trial, weekly maintenance doses were 5 mg, 10 mg or 15 mg, reached by starting at 2.5 mg for four weeks and escalating by 2.5 mg roughly every four weeks. These are trial figures for a 72-week study, not a recommended personal dose. What is appropriate for any individual is a question for a qualified healthcare professional.

How do you reconstitute tirzepatide?

A lyophilised vial is a freeze-dried powder that must be dissolved in bacteriostatic water before any dose can be drawn. The water volume you add sets the concentration and therefore the number of syringe units per milligram. Work the numbers out first with the peptide reconstitution calculator; this page explains the concept, not a personal dose.

Why start at 2.5 mg?

To manage gastrointestinal tolerability. Nausea, diarrhoea, vomiting and constipation were the most commonly reported events in the trials and were most frequent while the dose was rising. The 2.5 mg starting dose is a treatment-initiation step, not a maintenance dose; holding it for four weeks before the first increase gives that tolerance time to build.

How long does titration take?

In the trials, escalation ran no sooner than every four weeks, so reaching the top 15 mg tier from a 2.5 mg start took about twenty weeks; the dose was then held for the remainder of the treatment period. Arms with a lower maintenance target reached it sooner.

Is there an approved tirzepatide dose?

Unlike some investigational peptides, tirzepatide is an approved molecule, and its labelling describes a titration from a 2.5 mg initiation dose up to a 15 mg weekly maximum in 2.5 mg steps. That labelled schedule describes a finished, approved medicine — not a research compound, and not personal guidance for you. BeSkinny supplies tirzepatide for research use only; any real-world dosing decision belongs with a registered healthcare professional.

Sources

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. NEJM and PubMed
• Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515. NEJM and PubMed
• Zepbound (tirzepatide) injection — Prescribing Information, Drugs@FDA. U.S. Food and Drug Administration. accessdata.fda.gov
• Mounjaro (tirzepatide) injection — Prescribing Information, Drugs@FDA. U.S. Food and Drug Administration. accessdata.fda.gov
• Drugs.com. Tirzepatide — uses, dosage, side effects. drugs.com